Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8787297 | Gaceta Mexicana de Oncología | 2016 | 4 Pages |
Abstract
If chemoembolisation has to delayed, it is feasible to use sorafenib as a bridging therapy, which can also serve to avoid delay in palliative therapy if the patient turns out not to be a candidate for local therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Nora Hilda Chávez Hernández, Alejandro Antonio Sánchez Cruz,